Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | XPO1 | O14980 | 2/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30764789 | 1.00 | KDR (0.41) | KDRMEN1KMT2AMAPTMAPK1 | |
| SCHEMBL21617050 | 0.89 | SCN9A (0.50) | KDRMEN1KMT2AMAPTXPO1 | |
| SCHEMBL30603856 | 0.85 | MEN1 (0.60) | KDRMEN1KMT2AMAPTMAPK1 | |
| SCHEMBL29110571 | 0.85 | MEN1 (0.60) | KDRMEN1KMT2AMAPTMAPK1 | |
| SCHEMBL18434270 | 0.84 | RAB9A (0.55) | MEN1KMT2AMAPTMAPK1XPO1 | |
| SCHEMBL1702145 | 0.82 | CTSC (0.51) | SYKDHFRCTSC | |
| SCHEMBL21621090 | 0.82 | SCN9A (0.42) | XPO1ALDH1A1SYKSCN9AKDM4E | |
| SCHEMBL21617070 | 0.82 | XPO1 (0.42) | MEN1KMT2AXPO1ALDH1A1SYK | |
| SCHEMBL30764783 | 0.82 | XPO1 (0.42) | MEN1KMT2AXPO1ALDH1A1SYK | |
| SCHEMBL21617073 | 0.82 | SCN9A (0.48) | MEN1KMT2AMAPTMAPK1XPO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035348-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2026-02-05 | — | — | US | disclosed |
| US-12479802-B2 | Phenyl-n-quinoline derivatives for treating a RNA virus infection | ABIVAX (FR) | 2025-11-25 | — | — | US | disclosed |
| US-20240308964-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2024-09-19 | — | — | US | disclosed |
| US-12084422-B2 | Phenyl-n-quinoline derivatives for treating a RNA virus infection | ABIVAX (FR) | 2024-09-10 | — | — | US | disclosed |
| CN-112566899-B | phenyl-N-quinoline derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20210309611-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-10-07 | — | — | US | disclosed |
| US-20210309611-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-10-07 | — | — | US | disclosed |
| CN-112566899-A | phenyl-N-quinoline derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2020011810-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308964-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ORC3, NSUN3, POLR2H | KDR 3485/4885MEN1 4277/4885KMT2A 4178/4885 |
| US-12084422-B2 | Phenyl-n-quinoline derivatives for treating a RNA virus infection | ORC3, NSUN3, POLR2H | KDR 3485/4885MEN1 4277/4885KMT2A 4178/4885 |
| US-20260035348-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | SARS1, NDUFC2, CLIC1 | KDR 2868/4885MEN1 3696/4885KMT2A 2282/4885 |
| US-12479802-B2 | Phenyl-n-quinoline derivatives for treating a RNA virus infection | ORC3, NSUN3, POLR2H | KDR 3485/4885MEN1 4277/4885KMT2A 4178/4885 |
| US-20210309611-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ORC3, NSUN3, POLR2H | KDR 3485/4885MEN1 4277/4885KMT2A 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.